Literature DB >> 23891082

The use of surface immobilization of P-selectin glycoprotein ligand-1 on mesenchymal stem cells to facilitate selectin mediated cell tethering and rolling.

Chi Y Lo1, Aristotelis Antonopoulos, Anne Dell, Stuart M Haslam, Techung Lee, Sriram Neelamegham.   

Abstract

Mesenchymal stem/stromal cells (MSCs) are an important candidate for cell-based therapy since they can be easily isolated and expanded, secrete beneficial paracrine factors, and differentiate into multiple lineages. Since the endothelium at sites of injury and inflammation often express adhesion molecules belonging to the selectin family, methods to endow MSCs with selectin-ligands can enhance the efficacy of cell delivery and tissue engraftment. Here, we describe a construct 19Fc[FUT7(+)], where the first 19 amino acids of the pan-selectin ligand PSGL-1 (P-selectin glycoprotein ligand-1) was fused to a human IgG1. When expressed in HEK293T cells over-expressing the α(1,3)fucosyltransferase FUT7, 19Fc[FUT7(+)] is decorated by a core-2 sialyl Lewis-X sialofucosylated O-glycan. The non-covalent coupling of this protein onto MSC surface using palmitated protein G (PPG) enhanced cell binding to E- and P-selectin under hydrodynamic shear, without altering MSC multipotency. MSCs functionalized with 19Fc[FUT7(+)] were captured/tethered onto stimulated endothelial cell monolayers at wall shear stresses up to 4 dyn/cm(2). Once captured, the cells rolled robustly up to the highest shear stress tested, 10 dyn/cm(2). Unlike previous work where MSCs could only be captured onto selectin-bearing substrates at low or no-flow conditions, the current work presents a 'glycan engineering' strategy to enable leukocyte-like capture and rolling.
© 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  19Fc and 19Fc[FUT7(+)]; Adhesion molecule; Blood flow; Cell adhesion; Endothelial cell; Fusion protein of PSGL-1 N-terminal peptide fused to human IgG1 Fc expressed in either wild-type HEK293T (HEK) or HEK overexpressing α(1,3)fucosyltransferase, FUT7; Mesenchymal stem cells; PPG; Palmitated-protein G conjugate; Recombinant protein

Mesh:

Substances:

Year:  2013        PMID: 23891082      PMCID: PMC3943335          DOI: 10.1016/j.biomaterials.2013.07.033

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  43 in total

1.  Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells.

Authors:  Brigitte Rüster; Stephan Göttig; Ralf J Ludwig; Roxana Bistrian; Stefanie Müller; Erhard Seifried; Jens Gille; Reinhard Henschler
Journal:  Blood       Date:  2006-08-08       Impact factor: 22.113

Review 2.  Mesenchymal stem cells in health and disease.

Authors:  Antonio Uccelli; Lorenzo Moretta; Vito Pistoia
Journal:  Nat Rev Immunol       Date:  2008-09       Impact factor: 53.106

Review 3.  Leucocyte adhesion under flow conditions: principles important in tissue engineering.

Authors:  D A Jones; C W Smith; L V McIntire
Journal:  Biomaterials       Date:  1996-02       Impact factor: 12.479

Review 4.  Mesenchymal stem cells for systemic therapy: shotgun approach or magic bullets?

Authors:  Susan M Millard; Nicholas M Fisk
Journal:  Bioessays       Date:  2012-11-26       Impact factor: 4.345

5.  Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics.

Authors:  T S Raju; J B Briggs; S M Borge; A J Jones
Journal:  Glycobiology       Date:  2000-05       Impact factor: 4.313

6.  Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.

Authors:  Katarina Le Blanc; Francesco Frassoni; Lynne Ball; Franco Locatelli; Helene Roelofs; Ian Lewis; Edoardo Lanino; Berit Sundberg; Maria Ester Bernardo; Mats Remberger; Giorgio Dini; R Maarten Egeler; Andrea Bacigalupo; Willem Fibbe; Olle Ringdén
Journal:  Lancet       Date:  2008-05-10       Impact factor: 79.321

7.  Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance.

Authors:  Zhaokang Cheng; Lailiang Ou; Xin Zhou; Fei Li; Xiaohua Jia; Yinguo Zhang; Xiaolei Liu; Yuming Li; Christopher A Ward; Luis G Melo; Deling Kong
Journal:  Mol Ther       Date:  2008-02-05       Impact factor: 11.454

8.  Silencing α1,3-fucosyltransferases in human leukocytes reveals a role for FUT9 enzyme during E-selectin-mediated cell adhesion.

Authors:  Alexander Buffone; Nandini Mondal; Rohitesh Gupta; Kyle P McHugh; Joseph T Y Lau; Sriram Neelamegham
Journal:  J Biol Chem       Date:  2012-11-28       Impact factor: 5.157

9.  Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution.

Authors:  Israel M Barbash; Pierre Chouraqui; Jack Baron; Micha S Feinberg; Sharon Etzion; Ariel Tessone; Liron Miller; Esther Guetta; Dov Zipori; Laurence H Kedes; Robert A Kloner; Jonathan Leor
Journal:  Circulation       Date:  2003-08-04       Impact factor: 29.690

10.  Structural characterisation of neutrophil glycans by ultra sensitive mass spectrometric glycomics methodology.

Authors:  Ponnusamy Babu; Simon J North; Jihye Jang-Lee; Sara Chalabi; Kathryn Mackerness; Sean R Stowell; Richard D Cummings; Sara Rankin; Anne Dell; Stuart M Haslam
Journal:  Glycoconj J       Date:  2009-11       Impact factor: 2.916

View more
  20 in total

Review 1.  Programming Cell-Cell Interactions through Non-genetic Membrane Engineering.

Authors:  Clifford M Csizmar; Jacob R Petersburg; Carston R Wagner
Journal:  Cell Chem Biol       Date:  2018-06-14       Impact factor: 8.116

Review 2.  Homing and migration of mesenchymal stromal cells: How to improve the efficacy of cell therapy?

Authors:  Ann De Becker; Ivan Van Riet
Journal:  World J Stem Cells       Date:  2016-03-26       Impact factor: 5.326

Review 3.  Strategies for cell membrane functionalization.

Authors:  James Pk Armstrong; Adam W Perriman
Journal:  Exp Biol Med (Maywood)       Date:  2016-05

4.  Cell surface glycoengineering improves selectin-mediated adhesion of mesenchymal stem cells (MSCs) and cardiosphere-derived cells (CDCs): Pilot validation in porcine ischemia-reperfusion model.

Authors:  Chi Y Lo; Brian R Weil; Beth A Palka; Arezoo Momeni; John M Canty; Sriram Neelamegham
Journal:  Biomaterials       Date:  2015-09-25       Impact factor: 12.479

5.  Engineering Reversible Cell-Cell Interactions with Lipid Anchored Prosthetic Receptors.

Authors:  Clifford M Csizmar; Jacob R Petersburg; Alex Hendricks; Lawrence A Stern; Benjamin J Hackel; Carston R Wagner
Journal:  Bioconjug Chem       Date:  2018-03-23       Impact factor: 4.774

6.  Mesenchymal Stem Cell Deformability and Implications for Microvascular Sequestration.

Authors:  Herbert H Lipowsky; Daniel T Bowers; Brittany L Banik; Justin L Brown
Journal:  Ann Biomed Eng       Date:  2018-01-19       Impact factor: 3.934

Review 7.  Engineering mesenchymal stem cells for regenerative medicine and drug delivery.

Authors:  Ji Sun Park; Smruthi Suryaprakash; Yeh-Hsing Lao; Kam W Leong
Journal:  Methods       Date:  2015-03-11       Impact factor: 3.608

8.  Engineered Biomaterials to Enhance Stem Cell-Based Cardiac Tissue Engineering and Therapy.

Authors:  Anwarul Hasan; Renae Waters; Boustany Roula; Rahbani Dana; Seif Yara; Toubia Alexandre; Arghya Paul
Journal:  Macromol Biosci       Date:  2016-03-08       Impact factor: 4.979

9.  Glycoengineering of E-Selectin Ligands by Intracellular versus Extracellular Fucosylation Differentially Affects Osteotropism of Human Mesenchymal Stem Cells.

Authors:  Brad Dykstra; Jungmin Lee; Luke J Mortensen; Haixiao Yu; Zhengliang L Wu; Charles P Lin; Derrick J Rossi; Robert Sackstein
Journal:  Stem Cells       Date:  2016-07-17       Impact factor: 6.277

Review 10.  Cell augmentation strategies for cardiac stem cell therapies.

Authors:  Raquel Cruz-Samperio; Millie Jordan; Adam Perriman
Journal:  Stem Cells Transl Med       Date:  2021-03-04       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.